185 related articles for article (PubMed ID: 28795252)
1. IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
Palmieri C; Szydlo R; Miller M; Barker L; Patel NH; Sasano H; Barwick T; Tam H; Hadjiminas D; Lee J; Shaaban A; Nicholas H; Coombes RC; Kenny LM
Breast Cancer Res Treat; 2017 Nov; 166(2):527-539. PubMed ID: 28795252
[TBL] [Abstract][Full Text] [Related]
2.
Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM
Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer incorporating non-linear red blood cell uptake.
Parra-Guillen ZP; Cendrós Carreras JM; Peraire C; Obach R; Prunynosa J; Chetaille E; Trocóniz IF
Pharm Res; 2015 Apr; 32(4):1493-504. PubMed ID: 25355461
[TBL] [Abstract][Full Text] [Related]
4. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
5. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
[TBL] [Abstract][Full Text] [Related]
7. Steroid sulfatase inhibitors: the current landscape.
Anbar HS; Isa Z; Elounais JJ; Jameel MA; Zib JH; Samer AM; Jawad AF; El-Gamal MI
Expert Opin Ther Pat; 2021 Jun; 31(6):453-472. PubMed ID: 33783295
[No Abstract] [Full Text] [Related]
8. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; Hogben K; De Nguyen Q; Coombes RC; Aboagye EO
Nucl Med Commun; 2011 Nov; 32(11):997-1004. PubMed ID: 21862943
[TBL] [Abstract][Full Text] [Related]
9. IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Palmieri C; Stein RC; Liu X; Hudson E; Nicholas H; Sasano H; Guestini F; Holcombe C; Barrett S; Kenny L; Reed S; Lim A; Hayward L; Howell S; Coombes RC;
Breast Cancer Res Treat; 2017 Sep; 165(2):343-353. PubMed ID: 28612226
[TBL] [Abstract][Full Text] [Related]
10. Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
Palmieri C; Januszewski A; Stanway S; Coombes RC
Expert Rev Anticancer Ther; 2011 Feb; 11(2):179-83. PubMed ID: 21342037
[TBL] [Abstract][Full Text] [Related]
11. Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Stanway SJ; Delavault P; Purohit A; Woo LW; Thurieau C; Potter BV; Reed MJ
Oncologist; 2007 Apr; 12(4):370-4. PubMed ID: 17470679
[TBL] [Abstract][Full Text] [Related]
12. Design, structure-activity relationships, and enzyme kinetic studies of tricyclic and tetracyclic coumarin-based sulfamates as steroid sulfatase inhibitors.
Chiu PF; Lin IC; Lu YL; Chang CN; Chan HY; Lin TS; Tsai KC; Hsieh YSY; Chen MJ; Lin MH; Liang PH
Bioorg Chem; 2023 Sep; 138():106581. PubMed ID: 37172437
[TBL] [Abstract][Full Text] [Related]
13. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Kenny L; Coombes RC; Vigushin DM; Al-Nahhas A; Shousha S; Aboagye EO
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1339-47. PubMed ID: 17333178
[TBL] [Abstract][Full Text] [Related]
14. A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.
Coombes RC; Cardoso F; Isambert N; Lesimple T; Soulié P; Peraire C; Fohanno V; Kornowski A; Ali T; Schmid P
Breast Cancer Res Treat; 2013 Jul; 140(1):73-82. PubMed ID: 23797179
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).
Woo LW; Ganeshapillai D; Thomas MP; Sutcliffe OB; Malini B; Mahon MF; Purohit A; Potter BV
ChemMedChem; 2011 Nov; 6(11):2019-34. PubMed ID: 21990014
[TBL] [Abstract][Full Text] [Related]
16. Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism.
Sang X; Han H; Poirier D; Lin SX
J Steroid Biochem Mol Biol; 2018 Oct; 183():80-93. PubMed ID: 29803725
[TBL] [Abstract][Full Text] [Related]
17. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.
Marti-Climent JM; Dominguez-Prado I; Garcia-Velloso MJ; Boni V; Peñuelas I; Toledo I; Richter JA
Rev Esp Med Nucl Imagen Mol; 2014; 33(5):280-5. PubMed ID: 25066253
[TBL] [Abstract][Full Text] [Related]
18. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
[TBL] [Abstract][Full Text] [Related]
19. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
20. Development of steroid sulfatase inhibitors.
Woo LW; Purohit A; Potter BV
Mol Cell Endocrinol; 2011 Jul; 340(2):175-85. PubMed ID: 21238537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
